M Susa
Overview
Explore the profile of M Susa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
512
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Missbach M, Altmann E, Susa M
Curr Opin Drug Discov Devel
. 2009 Aug;
3(5):541-8.
PMID: 19649882
Inhibition of tyrosine kinase signaling has become increasingly important as a therapeutic approach for a variety of diseases, initially for cancer, but also for inflammatory and non-malignant hyperproliferative diseases (psoriasis)...
2.
Bengel D, Susa M, Schreiber H, Ludolph A, Tumani H
Eur J Neurol
. 2007 Aug;
14(9):1067-70.
PMID: 17718704
A 40-year-old diabetic woman was diagnosed with rhinocerebral mucormycosis. Cerebral mucormycosis is an acute life-threatening disease, which is caused by fungi of the class Phycomycetae. Clinical suspicion and detection of...
3.
Susa M, Teti A
Drug News Perspect
. 2003 Aug;
13(3):169-75.
PMID: 12937607
More than 20 years after its discovery, tyrosine kinase Src is still the focus of intense research, in both academia and the pharmaceutical industry. A prototype for non-receptor tyrosine kinases...
4.
Recchia I, Rucci N, Festuccia C, Bologna M, Mackay A, Migliaccio S, et al.
Eur J Cancer
. 2003 Aug;
39(13):1927-35.
PMID: 12932673
Two bona fide c-Src inhibitors, denominated CGP77675 and CGP76030, reduced in a time- and concentration-dependent manner (i) the proliferation of the PC3 prostate carcinoma cell line, as assessed by the...
5.
Susa M, GLATT M, Teti A
Curr Med Chem Anticancer Agents
. 2003 Apr;
1(3):313-29.
PMID: 12678761
A variety of cancers are associated with bone. Primary tumors can arise in bone, common cancers, such as those of breast and prostate origin, metastasize to bone, and multiple myeloma...
6.
Freitas F, Jeschke M, Majstorovic I, Mueller D, Schindler P, Voshol H, et al.
Bone
. 2002 Jan;
30(1):99-108.
PMID: 11792571
Fluoroaluminate is a G-protein activator, it stimulates osteoblastic cells in culture, and is a bone-forming agent in vivo. To elucidate the mechanisms of G-protein-mediated action of fluoroaluminate in osteoblasts, we...
7.
Voisard R, Huber N, Baur R, Susa M, Ickrath O, Both A, et al.
BMC Mol Biol
. 2001 Sep;
2:7.
PMID: 11532196
Background: Activation of nuclear factor-kappaB (NF-kappaB) is one of the key events in early atherosclerosis and restenosis. We hypothesized that tumor necrosis factor-alpha (TNF-alpha) induced and NF-kappaB mediated expression of...
8.
Voisard R, Voglic S, Baur R, Susa M, Koenig W, Hombach V
Coron Artery Dis
. 2001 Aug;
12(5):401-11.
PMID: 11491206
Objective: The importance of peripheral blood leukocytes for the development of early atherosclerosis and restenosis has confronted cardiologists with classical hematologic issues. Three-dimensional human coronary in-vitro units of leukocyte attack...
9.
Rozdzinski E, Marre R, Susa M, Wirth R
Microb Pathog
. 2001 Apr;
30(4):211-20.
PMID: 11312614
Aggregation substance (AS) of Enterococcus faecalis (E. faecalis), a sex pheromone plasmid encoded cell surface protein, mediates the formation of bacterial aggregates, thereby promoting plasmid transfer. The influence of pAD1-encoded...
10.
Altmann E, Missbach M, Green J, Susa M, Wagenknecht H, Widler L
Bioorg Med Chem Lett
. 2001 Mar;
11(6):853-6.
PMID: 11277536
7-Heterocyclyl-5-aryl-pyrrolo[2,3-d]pyrimidines represent a new class of highly potent and selective inhibitors of the tyrosine kinase pp60(c-Src).